ADC Therapeutics SA (NYSE:ADCT) Receives $7.83 Consensus Price Target from Brokerages

Shares of ADC Therapeutics SA (NYSE:ADCT) have been assigned a consensus rating of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $7.83.

Several equities research analysts have recently commented on ADCT shares. Morgan Stanley decreased their price target on ADC Therapeutics from $5.00 to $2.00 in a research note on Tuesday, July 11th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of ADC Therapeutics in a research report on Tuesday, July 25th. Royal Bank of Canada dropped their price target on ADC Therapeutics from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, August 9th. Finally, JPMorgan Chase & Co. upgraded shares of ADC Therapeutics from an “underweight” rating to a “neutral” rating in a research report on Thursday, August 10th.

ADC Therapeutics Price Performance

Shares of NYSE ADCT opened at $1.07 on Thursday. The company has a debt-to-equity ratio of 2.57, a quick ratio of 4.88 and a current ratio of 5.12. ADC Therapeutics has a one year low of $1.05 and a one year high of $6.58. The firm has a market capitalization of $82.19 million, a P/E ratio of -0.47 and a beta of 1.01. The company’s fifty day moving average is $1.49 and its two-hundred day moving average is $2.07.

ADC Therapeutics (NYSE:ADCT) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.14). ADC Therapeutics had a negative net margin of 98.33% and a negative return on equity of 325.79%. The company had revenue of $19.28 million during the quarter, compared to analyst estimates of $34.77 million. Analysts forecast that ADC Therapeutics will post -2.25 EPS for the current fiscal year.

Institutional Trading of ADC Therapeutics

A number of large investors have recently made changes to their positions in the stock. Prospera Financial Services Inc purchased a new stake in ADC Therapeutics in the 1st quarter worth approximately $25,000. HRT Financial LP acquired a new position in ADC Therapeutics in the first quarter valued at $31,000. Quantbot Technologies LP acquired a new position in ADC Therapeutics in the second quarter valued at $38,000. Virtu Financial LLC purchased a new position in ADC Therapeutics during the second quarter worth about $40,000. Finally, Acadian Asset Management LLC acquired a new stake in ADC Therapeutics in the 2nd quarter worth about $45,000. Institutional investors and hedge funds own 67.29% of the company’s stock.

About ADC Therapeutics

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL).